Adapt Pharma Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Adapt Pharma Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10983
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:59
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アイルランド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥100,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Adapt Pharma Ltd (Adapt Pharma) is a drug discovery and development company that manufactures and distributes prescription medicines. The company’s product Narcan (naloxone hydrochloride) nasal spray is an opioid antagonist that is indicated for the emergency treatment of opioid overdose as manifested by respiratory and central nervous system depression. It also develops treatments for patients with special medical conditions. Adapt Pharma offers its patients with specialty medical conditions. The company serves firefighters, first responders, law enforcement, and departments of health, educational facilities and community-based organizations, among others. The company has its operations in the US and Ireland. Adapt Pharma is headquartered in Dublin City, Ireland.

Adapt Pharma Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Adapt Pharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Adapt Pharma Enters into Co-Development Agreement with Profector Life Sciences 11
Licensing Agreements 12
Lightlake Therapeutics Enters into Licensing Agreement with Adapt Pharma Operations 12
Equity Offering 13
Adapt Pharma Raises USD95 Million in Private Placement of Shares 13
Acquisition 14
Emergent BioSolutions Acquires Adapt Pharma for USD735 Million 14
Adapt Pharma Ltd – Key Competitors 16
Adapt Pharma Ltd – Key Employees 17
Adapt Pharma Ltd – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Recent Developments 19
Product News 19
12/20/2017: Opiant Pharmaceuticals Announces Significant Financial Developments Related to NARCAN Nasal Spray for Opioid Overdose 19
11/03/2017: Adapt Pharma Presents Human Factors Study Data on Usability of NARCAN (naloxone HCl) Nasal Spray at the 41st Association for Medical Education & Research in Substance Abuse Annual National Conference 20
10/24/2018: Emergent BioSolutions to offer all public libraries and YMCAs in the U.S. free opioid awareness education and NARCAN (naloxone HCl) Nasal Spray 21
10/24/2017: Walgreens Stocking Life Saving Narcan Nasal Spray in All Pharmacies Nationwide 22
10/17/2017: Adapt Pharma Launches Roll Call Training Video to Educate Law Enforcement on NARCAN (naloxone HCl) Nasal Spray 4mg 23
09/15/2017: Opiant Pharmaceuticals Provides an Update on NARCAN Nasal Spray 24
08/10/2017: Opiant Pharmaceuticals Announces Additional $3.75 Million Payment From NARCAN Nasal Spray Royalty Monetization 25
07/12/2018: Aetna Donates Narcan to Wayne County 26
06/26/2018: Albertsons Companies Offers Increased Access to Naloxone 27
06/06/2017: Survey Data Published on Community Use of NARCAN (naloxone HCI) Nasal Spray 4 mg to Help Reverse Opioid-Related Overdose – Current Medical Research and Opinion Journal 28
05/29/2018: ADAPT Pharma Launches New Online Platform for NARCAN 29
05/09/2018: Quebec Government makes NARCAN Nasal Spray free to anyone 14 years or older through Free naloxone program 30
04/30/2018: A Retrospective Analysis & Literature Review Published in Pain Management on the Pharmacokinetic Properties of Naloxone Approved for Community Use Highlights Bioequivalence of Dose & Usability 31
04/26/2018: Adapt Pharma donates 20,000 doses of NARCAN (naloxone HCl) Nasal Spray to the National Council for Behavioral Health and its Residential Treatment Member Organizations 32
04/25/2018: A Retrospective Literature Review Published in Pain Management on Prescribing Naloxone for Opioid Overdose Intervention Highlights Opportunities to Expand Community Access to Help Reduce Fatalities 33
04/24/2017: Emergency opioid treatment NARCAN Nasal Spray added to NIHB Program in Canada 34
04/11/2017: Ontario ministries make NARCAN Nasal Spray available to general public 35
04/10/2017: Adapt Pharma Expands Free NARCAN Nasal Spray Program to U.S. Colleges and Universities 36
04/09/2018: Adapt Pharma Welcomes Canadian & Ontario Governments Programs Providing NARCAN (naloxone HCl) Nasal Spray Free of Charge to NIHB Clients and All Ontarians through Pharmacies 37
04/05/2018: ADAPT Pharma Welcomes Surgeon General Naloxone Advisory 39
04/05/2018: CVS Health Expands Efforts to Educate Patients about Naloxone 40
04/04/2018: Cardinal Health Begins Donation of Over 80,000 Doses of Life-Saving Narcan for Distribution to Law Enforcement and First Responders in Appalachia 41
03/27/2017: Opiant Pharmaceuticals Announces Results of Positron Emission Tomography Study of Naloxone Nasal Spray 42
03/19/2018: ADAPT Pharma Expands Program Offering Free NARCAN (naloxone HCl) Nasal Spray to Eligible Schools and Universities 43
03/16/2017: New Data Presented on Adapt Pharmas Community Use of Narcan Nasal Spray 4 mg to Reverse Opioid-Related Overdose 44
03/05/2018: Adapt Pharma Expands Technical and R&D Teams 45
02/28/2017: Adapt Pharma Marks One-Year Anniversary of NARCAN Nasal Spray (naloxone HCl) 4mg Launch in the U.S. 46
02/13/2018: Aptar and Adapt Pharma Donate 5,000 Doses of NARCAN to Opioid Crisis Coalitions in Illinois 47
02/08/2018: Opiant Pharmaceuticals to Record Approximately $11.7 Million in Royalty and Milestone Payments Related to 2017 Sales of NARCAN Nasal Spray for Opioid Overdose 48
01/31/2018: Aegis Selects NARCAN (naloxone HCl) Nasal Spray to Help Combat Opioid Epidemic, Increasing Access to Life-saving Treatment in LA County 49
01/30/2017: Kroger Pharmacies to Increase Access to Naloxone in North Texas, East Texas and Southeast Texas 50
01/26/2017: Opiant Pharmaceuticals Announces FDA Approval of 2mg Formulation of NARCAN (naloxone HCI) Nasal Spray 51
01/09/2017: Opiant Pharmaceuticals Featured in Recent Media Highlighting NARCAN Nasal Spray and Heroin Vaccine Development 52
Product Approvals 53
Aug 04, 2017: Opiant Pharmaceuticals Announces FDA Orange Book Listing for New NARCAN Nasal Spray Patent 53
Jun 27, 2017: Opiant Pharmaceuticals Announces FDA Orange Book Listing for New NARCAN Nasal Spray Patent 54
Mar 09, 2017: Opiant Pharmaceuticals Announces FDA Orange Book Listings for Two New NARCAN Nasal Spray Patents 55
Feb 21, 2017: Adapt Pharma Announces European Marketing Application Filed For Naloxone Hydrochloride Nasal Spray 56
Jan 25, 2017: NARCAN (naloxone HCl) Nasal Spray 2mg Approved by US Food and Drug Administration 57
Clinical Trials 58
Jan 11, 2017: Opiant Pharmaceuticals Announces 2017 Corporate and Clinical Goals 58
Appendix 59
Methodology 59
About GlobalData 59
Contact Us 59
Disclaimer 59

List of Tables
Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Adapt Pharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Adapt Pharma Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Adapt Pharma Enters into Co-Development Agreement with Profector Life Sciences 11
Lightlake Therapeutics Enters into Licensing Agreement with Adapt Pharma Operations 12
Adapt Pharma Raises USD95 Million in Private Placement of Shares 13
Emergent BioSolutions Acquires Adapt Pharma for USD735 Million 14
Adapt Pharma Ltd, Key Competitors 16
Adapt Pharma Ltd, Key Employees 17
Adapt Pharma Ltd, Subsidiaries 18

List of Figures
Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Adapt Pharma Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Lotte Chemical Corp (011170):企業の財務・戦略的SWOT分析
    Lotte Chemical Corp (011170) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • MAN SE:企業の戦略・SWOT・財務分析
    MAN SE - Strategy, SWOT and Corporate Finance Report Summary MAN SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • Accent Resources N.L.:企業の戦略・SWOT・財務情報
    Accent Resources N.L. - Strategy, SWOT and Corporate Finance Report Summary Accent Resources N.L. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Driver Group Plc (DRV):企業の財務・戦略的SWOT分析
    Driver Group Plc (DRV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Blade Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Blade Therapeutics Inc (Blade Therapeutics) is a biopharmaceutical company which develops novel anti-fibrotic therapies to treat various fibrotic disorders. Its lead program is a small molecule inhibitor targeting an intracellular cysteine protease associated with fibrosis across diverse ind …
  • TUI Group:企業の戦略・SWOT・財務情報
    TUI Group - Strategy, SWOT and Corporate Finance Report Summary TUI Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • VolitionRX Ltd (VNRX):医療機器:M&Aディール及び事業提携情報
    Summary VolitionRX Ltd (VolitionRX) is a medical equipment provider that develops diagnostics tests for cancer and other conditions. The company develops Nucleosomics, a platform technology used for measurement and identification of nucleosomes in the blood. It develops tools for the diagnosis of va …
  • Elbit Systems Ltd:戦略・SWOT・企業財務分析
    Elbit Systems Ltd - Strategy, SWOT and Corporate Finance Report Summary Elbit Systems Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Cimentos de Portugal SGPS SA:企業の戦略的SWOT分析
    Cimentos de Portugal SGPS SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • The Ultimate Software Group, Inc. (ULTI):企業の財務・戦略的SWOT分析
    The Ultimate Software Group, Inc. (ULTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Arsanis Inc (ASNS):製薬・医療:M&Aディール及び事業提携情報
    Summary Arsanis Inc (Arsanis) is a clinical-stage biopharmaceutical company that focuses on the development of monoclonal antibody immunotherapies for the treatment of critical infectious diseases. The company’s pipeline product portfolio includes ASN100, for staphylococcus aureus; ASN500, targets r …
  • National Gas & Industrial Co. (2080):企業の財務・戦略的SWOT分析
    National Gas & Industrial Co. (2080) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • West African Development Bank:電力:M&Aディール及び事業提携情報
    Summary West African Development Bank (BOAD) is a public financial institution focused on the balanced development of its member countries of the West African Monetary Union (WAMU). The institution offers financial advisory services; guarantees of bond loans; financial assistance in project preparat …
  • Adams Resources & Energy, Inc.:企業の戦略・SWOT・財務分析
    Adams Resources & Energy, Inc. - Strategy, SWOT and Corporate Finance Report Summary Adams Resources & Energy, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • National Thermal Power Corporation Ltd:戦略・SWOT・企業財務分析
    National Thermal Power Corporation Ltd - Strategy, SWOT and Corporate Finance Report Summary National Thermal Power Corporation Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Prysmian S.p.A.:企業のM&A・事業提携・投資動向
    Prysmian S.p.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Prysmian S.p.A. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • EnCana Corporation:企業の戦略・SWOT・財務情報
    EnCana Corporation - Strategy, SWOT and Corporate Finance Report Summary EnCana Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • EV Energy Partners LP:企業のM&A・事業提携・投資動向
    EV Energy Partners LP - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's EV Energy Partners LP Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • State Street Corporation:企業のM&A・事業提携・投資動向
    State Street Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's State Street Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Sberbank Rossii:企業の戦略・SWOT・財務情報
    Sberbank Rossii - Strategy, SWOT and Corporate Finance Report Summary Sberbank Rossii - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆